Download - Advances in Clinical Neuroscience and Rehabilitation

More documents

Recommendations

Info

AWA R D S A N D A P P O I N T M E N T SFENS Photography WinnersAnnouncedA Scientific Photography contest with “ScientificPhenomena” and “The Lab Through Your Eyes” categorieswas launched by the FENS students’ committee for thefirst time at the 8th FENS Forum in July. The aim of theinitiative was that young scientists should show science ina new way. The prizes were sponsored by Olympus, Mentey Cerebro magazine and ACNR. Congratulations to thewinners of this first contest and thanks to all the scientistswho sent their photographs.Scientific Phenomena category: winner of the Jury Prize –“Fight and Surrender” by Carmen Agustín Pavón. Vox PopPrize – “Happy Hippos” by Chris Henstridge.The Lab Through Your Eyes category: Jury Prize – “In Searchof the Big Fish” by Anna Sendelbeck (see cover picture ofACNR this issue). Vox Pop - “PhD Title Recipe” by MarcoDavid Brockmann.You can see all the photographs in an exhibition on the Jumpthe FENS 2012 Facebook page.Nominations for UKABIFAwards 2012Do you know someone who deserves recognition for theinnovative or inspirational work that they do in the field ofAcquired Brain Injury (ABI)? If you do, then nominate themnow for one of two prestigious United Kingdom AcquiredBrain Injury (UKABIF) Awards.The UKABIF Award for Innovation is open to individuals ororganisations that make a difference in ABI; innovation by alawyer/law firm, clinician, care provider, social care worker,Naomi GilbertHena AhmadEd Robertseducational or voluntary sector provider or registeredcharity. The Stephen McAleese Award for Inspiration is foran individual in the field of ABI.To enter simply complete the form that can be found on theUKABIF website: www.ukabif.org.uk. The deadline for entriesis the 19th October 2012.Naomi Gilbert joins the TNANaomi Gilbert has joined the Trigeminal NeuralgiaAssociation UK as their new CEO. Naomi trained as a nurseat Guy’s Hospital and went on to become a surgical wardsister at St George’s Hospital in Tooting and then a nurseteacher. Following two years monitoring clinical trials at amajor pharmaceutical company, Naomi moved into thevoluntary sector.Further information from http://www.tna.org.uk/news.phpNew Appointments at ImperialCollege LondonDr Hena Ahmad joins the Neuro-Otology team inSeptember. She is currently working at Charing CrossHospital and will be looking at the use of non-invasivebrain stimulation techniques in understanding the brainmechanisms underlying symptoms in patients withdizziness and eye movement problems.Dr Ed Roberts has recently joined the Neuro-Otology teamas a post-doctoral researcher looking at the cerebralcortical mechanisms involved in chronic dizziness usingbrain stimulation and magnetic resonance imagingtechniques.Trobalt ® (Retigabine) Prescribing Information(Please refer to the full Summary of Product Characteristics before prescribing).Presentation ‘Trobalt tablets’ each containing retigabine equivalent to either: purple film coatedround tablets containing 50 mg retigabine; green film coated round tablets containing 100 mgretigabine; yellow film coated oblong tablets containing 200 mg retigabine; green film coatedoblong tablets containing 300 mg retigabine; purple film coated oblong tablets containing 400 mgretigabine. Indications Adjunctive treatment for partial onset seizures with or without secondarygeneralisation in adults aged 18 years and above. Dosage and Administration Trobalt must betaken orally in three divided doses each day. The maximum total daily starting dose is 300 mg(100 mg three times daily). Thereafter, the total daily dose is increased by a maximum of 150 mgevery week according to individual patient response and tolerability. An effective maintenancedose is expected between 600 mg/day and 1,200 mg/day. Renal impairment: No dose adjustmentis required in patients with mild renal impairment. A 50% reduction in the initial and maintenancedose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinineclearance 440 ms at baseline, an ECG should be recorded on reaching the maintenance dose. Psychiatricdisorders: Confusional state, psychotic disorders and hallucinations were reported in controlledclinical studies, it is recommended that patients are advised about the risk of these possibleeffects. Suicide risk: Suicidal ideation and behaviour have been reported in patients treated withanti epileptic agents in several indications. Patients (and caregivers of patients) should be advisedto seek medical advice if signs of suicidal ideation or behaviour emerge. Elderly (65 years of ageand above): Elderly patients may be at increased risk of central nervous system events, urinaryretention and atrial fibrillation. Retigabine must be used with caution in this population with areduced initial and maintenance dose recommended. As there is individual variation in response toall antiepileptic drug therapy, it is recommended that prescribers discuss with patients the specificissues of epilepsy and driving. Overdose In the event of overdose it is recommended that thepatient is given appropriate supportive therapy as clinically indicated, including ECG monitoring.Further management should be as recommended by the national poisons centre, whereavailable. Fertility, pregnancy and lactaction Trobalt is not recommended during pregnancyand in women of childbearing age not using contraception. It is unknown whether retigabine isexcreted in human breast milk. The effect of retigabine on human fertility has not been established.Drug interactions In vitro data indicated a low potential for interaction with other antiepilepticdrugs. Pooled analysis from clinical studies showed no clinically significant effect of the inducers(phenytoin, carbamazepine and phenobarbital) on retigabine clearance. Steady-state datafrom a limited number of patients in smaller studies indicate that phenytoin and carbamazepinecould reduce retigabine systemic exposure by 35% and 33% respectively. Trobalt interaction withdigoxin at therapeutic doses may increase digoxin serum concentrations. Retigabine may increasethe duration of some anaesthetics. Adverse reactions A dose relationship seems to exist betweendizziness, somnolence, confusional state, aphasia, coordination abnormal, tremor, balance disorder,memory impairment, gait disturbance, blurred vision and constipation. Metabolism and nutritiondisorders; common: weight increase, increased appetite. Psychiatric disorders; common: confusionalstate, psychotic disorders, hallucinations, disorientation, anxiety. Nervous system disorders; verycommon: dizziness, somnolence, common: amnesia, aphasia, coordination abnormal, vertigo,paraesthesia, tremor, balance disorders, memory impairment, dysphasia, dysarthria, disturbancein attention, gait disturbance, myoclonus, uncommon: hypokinesia. Eye disorders; common:diplopia, blurred vision. Gastrointestinal disorders; common: nausea, constipation, dyspepsia,dry mouth, uncommon: dysphagia. Hepatobiliary disorders; common: increased liver functiontests. Skin and subcutaneous disorders; uncommon: skin rash, hyperhidrosis. Renal and urinarydisorders; common: dysuria, urinary hesitation, haematuria, chromaturia, uncommon: urinaryretention, nephrolithiasis. General disorders and administrative site conditions; very common:fatigue, common: asthenia, malaise, peripheral oedema. Basic NHS costs Initiation packs of21 x 50 mg tablets and 42 x 100 mg tablets (EU/1/11/681/013) is £24.33. Maintenance packsof 21 and 84 x 50 mg tablets are (EU1/11/681/001) £4.87 and (EU/1/11/681/002) £19.46respectively. Maintenance packs of 21 and 84 x 100 mg tablets are (EU/1/11/681/004) £9.73and (EU/1/11/681/005) £38.93 respectively. Maintenance packs of 84 x 200 mg tablets are(EU/1/11/681/007) £77.86. Maintenance packs of 84 x 300 mg tablets are (EU/1/11/681/009)£116.78. Maintenance packs of 84 x 400 mg tablets are (EU/1/11/681/0011) £127.68. Legalcategory: POM Marketing authorisation holder Glaxo Group Limited. Berkeley Avenue,Greenford, Middlesex, UB6 0NN, United Kingdom. Further information is available from:Customer contact centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT.Email: customercontactuk@gsk.com Customer Services Freephone 0800 221441. Trobalt ®is a registered trademark of the GlaxoSmithKline group of companies. All rights reserved.Prescribing information last revised September 2011 UK/RTG/0151/11Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441Reference: 1. Trobalt Summary of Product Characteristics. GlaxoSmithKline; 2011.6 > ACNR > VOLUME 12 NUMBER 4 > SEPTEMBER/OCTOBER 2012
An element of changeA first-in-class potassium channelopener for the adjunctive treatmentof adults with partial epilepsy 1www.trobalt.co.ukUK/RTG/0051d/12Date of preparation: June 2012Prescribing information is available on the adjacent page
Page 1: ISSN 1473-9348 VOLUME 12 ISSUE 4 SE
Page 4: F RO M T H E E D I TO R ...Martin T
Page 9 and 10: At the centre of managing epilepsy
Page 11 and 12: R E V I E W A RT I C L ELeft panel:
Page 13 and 14: R E V I E W A RT I C L EFigure 1: H
Page 15 and 16: S P E C I A L F E AT U R EThe EuroI
Page 17 and 18: R E H A B I L I TAT I O N A RT I C
Page 19 and 20: R E H A B I L I TAT I O N A RT I C
Page 21 and 22: N E U RO LO GY I N A RTAn Artist’
Page 23 and 24: NEUROSCIENCE NURSING FEATUREClinica
Page 25 and 26: N E U RO S U RG E RY A RT I C L Emu
Page 27 and 28: N E U RO S U RG E RY A RT I C L ETa
Page 29 and 30: C O N F E R E N C E R E P O RT S39.
Page 31 and 32: C O N F E R E N C E R E P O RT SABN
Page 33 and 34: C O N F E R E N C E R E P O RT SThe
Page 35 and 36: Neuroradiology and Functional Neuro
Page 37 and 38: J O U R N A L R E V I E W SEditor
Page 39 and 40: N E W S R E V I E WFujifilm support

Download - Advances in Clinical Neuroscience and Rehabilitation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?